Drug Profile
Adomeglivant - Eli Lilly and Company
Alternative Names: LY-2409021Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Benzamides; Propionic acids; Small molecules
- Mechanism of Action Glucagon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 02 Oct 2023 Efficacy data from the PX-GRA trial in Diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 01 Oct 2015 Eli Lilly and Sofie Haedersdal University hospital initiate a clinical trial for Type-2 diabetes mellitus in Denmark by invitation only (NCT02669524)
- 01 May 2015 Eli Lilly completes a phase I trial in Healthy volunteers in USA (NCT02385084)